Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses

GuruFocus.com10-31

Net Revenue: $11.5 million for the third quarter of 2024. Net Loss: Approximately $2.8 million or 5 per share for Q3 2024. Operating Expenses: Increased 33% to $14.1 million in Q3 2024. Selling and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479372280?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 15:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479372280","market":"us","top_or_hot":-1,"title":"Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses","media":"GuruFocus.com","content":"<div>\n<p>Net Revenue: $11.5 million for the third quarter of 2024.\nNet Loss: Approximately $2.8 million or 5 per share for Q3 2024.\nOperating Expenses: Increased 33% to $14.1 million in Q3 2024.\nSelling and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cormedix-inc-crmd-q3-2024-070701807.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 15:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cormedix-inc-crmd-q3-2024-070701807.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Net Revenue: $11.5 million for the third quarter of 2024.\nNet Loss: Approximately $2.8 million or 5 per share for Q3 2024.\nOperating Expenses: Increased 33% to $14.1 million in Q3 2024.\nSelling and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cormedix-inc-crmd-q3-2024-070701807.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/cormedix-inc-crmd-q3-2024-070701807.html","article_id":"2479372280","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479372280","pubTimestamp":1730358421,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Net Revenue: $11.5 million for the third quarter of 2024.Net Loss: Approximately $2.8 million or 5 per share for Q3 2024.Operating Expenses: Increased 33% to $14.1 million in Q3 2024.Selling and Marketing Expense: Increased 66% to $6.7 million in Q3 2024.General and Administrative Expense: Increased 76% to $6.6 million in Q3 2024.R&D Expense: Decreased 73% to $0.7 million in Q3 2024.Cash and Cash Equivalents: $46 million as of September 30, 2024.Net Cash Used in Operations: $45 million for the nine months ended September 30, 2024.ATM Issuance Proceeds: Approximately $12.4 million in Q3 2024.GuruFocus has detected 4 Warning Signs with CRMD.For the complete transcript of the earnings call, please refer to the full earnings call transcript.The company has secured new agreements with two midsized dialysis operators and one large-scale operator, expanding access to 60% of US dialysis clinics.Cormedix Inc  expects to achieve positive EBITDA in the fourth quarter, indicating strong financial ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"Cormedix Inc(CRMD)2024年第三季度收益看涨期权亮点：在费用上升的情况下收入强劲增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"Net Revenue: $11.5 million for the third quarter of 2024.\nNet Loss: Approximately $2.8 million or 5 per share for Q3 2024.\nOperating Expenses: Increased 33% to $14.1 million in Q3 2024.\nSelling and Marketing Expense: Increased 66% to $6.7 million in Q3 2024.\nGeneral and Administrative Expense: Increased 76% to $6.6 million in Q3 2024.\nR&D Expense: Decreased 73% to $0.7 million in Q3 2024.\nCash and Cash Equivalents: $46 million as of September 30, 2024.\nNet Cash Used in Operations: $45 million for the nine months ended September 30, 2024.\nATM Issuance Proceeds: Approximately $12.4 million in Q3 2024.\n\n\nWarning! GuruFocus has detected 4 Warning Signs with CRMD.\n\nRelease Date: October 30, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nCormedix Inc (NASDAQ:CRMD) reported net revenue of $11.5 million for the third quarter, exceeding street consensus.\nThe company has secured new agreements with two midsized dialysis operators and one large-scale operator, expanding access to 60% of US dialysis clinics.\nCormedix Inc (NASDAQ:CRMD) expects to achieve positive EBITDA in the fourth quarter, indicating strong financial performance.\nThe company has a robust cash position with $46 million in cash and cash equivalents as of September 30, 2024.\nCormedix Inc (NASDAQ:CRMD) is actively working on expanding the label for DefenCath beyond hemodialysis, indicating potential for future growth.\n\n Negative Points \n\nThere is significant variability in fourth-quarter revenue projections due to the timing and scale of purchases by large dialysis organization (LDO) customers.\nThe setup for protocolizing DefenCath can take several weeks to a few months, potentially delaying revenue realization.\nOperating expenses increased by 33% in the third quarter compared to the same period in 2023, driven by higher selling, marketing, and G&A expenses.\nThe inpatient uptake process for DefenCath is expected to be longer and more consistent with traditional inpatient launches, delaying potential revenue from this segment.\nThe company is not providing specific revenue guidance for the fourth quarter due to uncertainties in customer onboarding timelines.\n\n Q & A Highlights \nQ: Can you speak to the use of DefenCath and whether it's driven by individual doctors or institutional protocols? Also, how do reimbursement dynamics compare to what you're seeing during the launch? A: The use of DefenCath is primarily driven by institutional protocols rather than individual doctors. Facilities are establishing criteria for its use and implementing based on those criteria. Regarding reimbursement, claims data shows a broad dispersion across Medicare Advantage, commercial, and Medicaid, but it starts with fee-for-service patients before expanding.\nQ: What are the stocking and order frequency dynamics for DefenCath, and how might macro factors like hurricanes affect distribution? A: Initial customers are holding about 10 days of inventory, while larger customers may hold 15 to 30 days. There was some disruption in the Southeast due to hurricanes, but trends have largely returned to normal.\nQ: How consistent are patient types across different providers, and is there an opportunity to educate providers on DefenCath usage? A: There is variability in how providers identify patient types for DefenCath, with some triaging based on benefits verification and others on high-risk criteria. This variability presents an opportunity to educate providers on broader usage.\nQ: What percentage of Q3 sales did US Renal Care represent, and can this partnership be replicated with other partners? A: US Renal Care accounted for over 90% of Q3 sales. The successful implementation with them is something we aim to replicate with other partners, particularly large dialysis organizations.\nQ: Can you provide insights into the nephrology community's feedback on DefenCath since its launch? A: Feedback has been positive, with no changes required to workflow and easy-to-understand clinical results. The nephrology community appreciates the product's effectiveness, and we continue to receive positive feedback from nurses, physicians, and patient advocates.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479372280"}